

## Dr. Carlos Bachier's Publications

### A. Published Articles:

1. **Bachier C**, Cangiano JL, Rodriguez-Sergeant C, Martinez-Maldonado M. Essential Hypertension: A Potential Risk Factor of Cataract Formation. *Hypertension*. 9(5), 1987.
2. **Bachier C**, Freytes CO, Salzman D, Castro J, Boldt D, Roodman GD, Harris K, Wiesner A, LeMaistre CF. Outcome of Patients Treated with Autologous Bone Marrow Transplantation for High Grade Non-Hodgkin's Lymphoma. *Autologous Bone Marrow and Blood Transplantation*. 8:391-397, 1995.
3. Freytes CO, **Bachier C**, Salzman D, Castro J, Boldt D, Roodman GD, Harris K, Sheridan-Leos N, LeMaistre CF. High Dose Chemotherapy with Stem Cell Rescue in Patients with Low Grade Lymphoma. *Autologous Marrow and Blood Transplantation*. 8: 397, 1995.
4. **Bachier C**, LeMaistre CF. Immunotoxin Therapy of Cancer: Rationale for Development and Future Potential. *Clinical Immunotherapy*. 3:450-460, 1995.
5. Hanania EG, Giles RE, Kavanagh J, Ellerson D, Zu Z, Su WY, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, **Bachier C**, Thall P, Cheng S, Hester J, Ostrove J, Byrd R, Cheng A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin R, Deisseroth AB. Results of MDR-1 Modification Trial Indicate that CFU-GM Do Not Contribute to Post Transplant Hematopoietic Recovery Following Intensive Systemic Therapy. *Proc Natl Acad Sci USA*. 93(26):15346-51, 1996.
6. Younes A, Ayoub P, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemester F, **Bachier C**, Preti A, Cabanillas F. Paclitaxel (Taxol<sup>®</sup>) for the treatment of lymphoma. *Annals of Oncology*. 8(1):S1-S3, 1997.
7. Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemester FB, Romaguera FB, Preti A, **Bachier C**, Cabanillas F. Phase I study of fludarabine and paclitaxel for treatment of low-grade non-Hodgkin's lymphoma. *Leukemia Lymphoma*. 26(1-2):77-82, 1997.
8. Younes A, Ayoub JP, Sarris A, Hagemester F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, **Bachier C**, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. *Br J Hematol*. 96(2):328-32, 1997.
9. Van Besien K, Ha CS, Murphy S, McLaughlin R, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemester H, Younes A, **Bachier C**, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults with Intermediate-Grade and Immunoblastic Lymphoma. *Blood*. 91(4):1178-1184, 1998.
10. Romaguera JE, Rodriguez DP, Carias L, Hagemester FB, McLaughlin P, Rodriguez MA, Sarris AH, Younes A, Preti A, **Bachier C**, Llerena E, Cabanillas F. Use of the international prognostic

- index and tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. *Leukemia Lymphoma*. 28(3-4):295-306, 1998.
11. **Bachier C**, Giles R, Ellerson D, Hanania E, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth AB. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. *Leukemia Lymphoma*. 32(3-4):279-288, 1999.
  12. **Bachier C**, Gokmen E, Teale J, Lanzkron S, Hougham M, Meneghetti C, Nanez A, Botello J, Huerta J, Childs C, Muller T, Armstrong D, Franklin W, Shpall EJ, LeMaistre CF. Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high dose chemotherapy for breast cancer. *Experimental Hematology*. 27:615-623, 1999.
  13. Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claston D, **Bachier C**, Greenberger J, Colonboeala I, Deisseroth AB. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210 bcr-abl positive 32D myeloid leukemia cells. *Oncogene*. 17(7):825-833, 1998.
  15. Guo XY, Balague C, Wang T, Randhawa G, **Bachier C**, Greenberger J, Arlinghaus R, Yuan Z, Kufe D, Deisseroth AB. The presence of the Rb-c-box peptide in cytoplasm results in inhibition of p210<sup>bcr-abl</sup> transformation function. *Oncogene*. 18:1589-1595, 1999.
  16. Younes A, Romaguera J, Mesina O, Hagemester F, Sarris AH, Rodriguez MA, McLaughlin P, HA Preti, **Bachier C**, Cabanillas F. Paclitaxel plus high-dose cyclophosphamide with filgrastim support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. *British Journal of Hematology*. 103:678-683, 1998.
  17. Z Rahman, Kavanagh J, Champlin R, Giles R, Hanania F, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, **Bachier C**, Ostrove J, Deisseroth A. Chemotherapy immediately following autologous stem cell transplantation in patients with advanced breast cancer. *Clinical Cancer Res*. 4(11):2717-21, 1998.
  18. Harris AH, Psyrris A, Gahemeister F, Romaguera J, McLaughlin P, Rodriguez MA, **Bachier C**, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Infusional Vinorelbine In Relapsed Or Refractory Lymphomas. *Leukemia Lymphoma*. 39(3-4):291-9, 2000.
  19. Shaughnessy PJ, Ririe DW, Ornstein DL, Kissack B, Bickford DJ, Molina R, Lanzkron S, **Bachier C**, Nanez A, LeMaistre CF. Graft Failure in a Patient with Systemic Lupus Erythematosus (SLE) Treated with High-Dose Immunosuppression and Autologous Stem Cell Rescue. *Bone Marrow Transplantation*. 27:221-224, 2001.
  20. Gokmen E, **Bachier C**, Raaphorst FM, Muller TE, Armstrong RD, LeMaistre CF, Teale JM. Ig Heavy Chain CDR3 Size Diversities Are Similar After Conventional Peripheral Blood and Ex Vivo Expanded Hematopoietic Cell Graft Transplants. *Bone Marrow Transplantation*. 27(4):413-424, 2001.

21. Gokmen E, **Bachier C**, Raaphorst FM, Muller T, Armstrong D, LeMaistre CF, Teale JM. Ex vivo-expanded hematopoietic cell graft recipients exhibit T cell repertoire diversity similar to that seen after conventional stem cell transplants. *J Hematother Stem Cell Res.* 10(1):53-66, 2001.
22. Pecora AL, Stiff P, LeMaistre CF, Bayer R, **Bachier C**, Goldberg SL, Parthasarathy M, Jennis AA, Smith AK, Douville J, Chen B, Armstrong RD, Mandalam RK, Preti R. A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation. *Bone Marrow Transplantation.* 28(3):295-303, 2001.
23. Shaughnessy PJ, Ornstein D, Ririe D, Callander N, Anderson JE, Pollack MS, Freytes CO, Cruz J, Rodriguez T, **Bachier C**, LeMaistre CF. Phase II Study of a Moderate Intensity Preparative Regimen with Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Diseases: The Texas Transplant Consortium Experience. *Biology of Blood and Marrow Transplantation.* 8:420-8, 2002.
24. LeMaistre, CF. Denileukin Diftitox for the Treatment of Steroid-Resistant Acute Graft vs. Host Disease. *Biology of Blood and Marrow Transplantation.* 11:188-193, 2005
25. **Carlos Bachier**. Prevention of Early CMV Infection in HSCT. *Blood and Marrow Transplantation Reviews.* 15(2):8-9, 2005.
26. Shaughnessy PJ, Alexander W, Tran H, Ririe D, Splichal J, Pollack M, **Bachier C**, LeMaistre CF. Phase I and Pharmacokinetic Study of Once-Daily Dosing of Intravenously Administered Busulfan in the Setting of a Reduced-Intensity Preparative Regimen and Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy for Renal Cell Carcinoma. *Military Med.* 171(2):000, 2006.
27. Shaughnessy PJ, **Bachier C**, LeMaistre C, Akay C, Pollock, BH, Gazitt Y. Granulocyte Colony-Stimulating Factor Mobilizes More Dendritic Cell Subsets Than Granulocyte-macrophage Colony-Stimulating Factor with No Polarization of Dendritic Cell Subsets in Normal Donors. *Stem Cells.* 24:1789-1797, 2006.

**B. Published Abstracts:**

1. Rodriguez-Sargent C, Martinez-Maldonado M, **Bachier C**, Cangiano JL. Vanadate Interfere with Fiske and Subarow Determination of Inorganic Phosphate. Proceedings of the 69th Meeting of the Federation of American Societies for Experimental Biology. 44:502, April 1985.
2. Adkins D, Salzman D, Boldt DH, Roodman RD, Kuhn J, Irvin R, Smith L, Lyons R, **Bachier C**, Freytes CO, LeMaistre CF. Phase I Trial of Dacarbazine (DTIC) given by 6 hour intravenous (IV) infusion with cyclophosphamide (C), etoposide (V), carmustine (B), and Autologous Bone Marrow Transplantation (ABMT) for Advanced Lymphoma. Proceedings of the 34th Annual Meeting of the American Society of Hematology. Anaheim California, December 4-8. *Blood*. 80(10):2054, 1992.
3. Freytes CO, Salzman D, **Bachier C**, Boldt DH, Roodman GD, Craig F, Castro J, LeMaistre CF. High Dose Chemotherapy with Stem Cell Rescue in Older Patients. *Blood*. 82(10):676, 1993.
4. Castro J, **Bachier C**, Freytes C, Harris K, Roodman D, Salzman D, Tami J, Meneghetti C, Sheridan-Leos N, LeMaistre CF. Cryopreserved Matched Related Donor Marrow Engrafts Promptly Following Allogeneic Bone Marrow Transplantation. Proceedings of the 36th Annual Meeting of the American Society of Hematology. *Blood*. 84(10):361, 1994.
5. **Bachier C**, Freytes CO, Salzman D, Castro J, Boldt D, Roodman GD, Harris K, Craig F, Wiesner A, LeMaistre CF. Bone Marrow Transplantation (BMT) for Adult Poor Risk High Grade Non Hodgkin's Lymphoma (HGBHL). Proceedings of the 36th Annual Meeting of the American Society of Hematology. *Blood*. 84(10):2799, 1994.
6. Freytes CO, **Bachier C**, Salzman D, Vukeljia S, Castro J, Boldt D, Roodman GD, Craig F, Harris K, Tsai T, Sheridan-Leos N, Hilsenbeck S, Tami J, Burrell L, LeMaistre CF. High Dose Chemotherapy with Autologous Stem Cell Rescue in Resistant or Recurrent Low Grade Lymphoma. Proceedings of the 36th Annual Meeting of the American Society of Hematology. *Blood*. 84(10):2821, 1994.
7. **Bachier C**, Craig F, Roodman GD. CD 34+ Stem Cell Selection and Immunomagnetic Purging (IMP) to Remove Chronic Lymphocytic (CLL) Leukemia Cells from Bone Marrow (BM). Proceedings of the 36th Annual Meeting of the American Society of Hematology. *Blood*. 84(10):2889, 1994.
8. **Bachier C**, Freytes CO, Salzman D, Castro J, Boldt D, Roodman GD, Harris K, Wiesner A, LeMaistre CF. Outcome of Patients Treated with Autologous Bone Marrow Transplantation for High Grade Non-Hodgkin's Lymphoma. 7th International Symposium on Autologous Bone Marrow Transplantation in Arlington, 1994.
9. Freytes CO, **Bachier C**, Salzman D, Castro J, Boldt D, Roodman GD, Harris K, Sheridan-Leos N, LeMaistre CF. High Dose Chemotherapy with Stem Cell Rescue in Patients with Low Grade Lymphoma. 7th International Symposium on Autologous Bone Marrow Transplantation in Arlington, 1994.

10. Castro J, Eckardt J, **Bachier C**, Freytes C, Salzman D, Tami J, Meneghetti C, Sheridan-Leos N, LeMaistre CF. Cytokine Support Following Allogeneic Bone Marrow Transplant Hastens Engraftment of Cryopreserved Matched Related Donor Marrow. Keystone Symposium, 1995. Abstract 361.
11. Freytes CO, Vukelja S, Salzman D, Tsai T, Callander N, Gokmen E, Rodriguez T, Castro J, Boldt D, Roodman GD, Hilsenbeck S, Adkins D, **Bachier C**, Craig F, Clare N, Weisner A, LeMaistre CF. Autologous Hematopoietic Stem Cell Transplantation for Poor Prognosis Low Grade Lymphoma. 25th Annual Meeting of the International Society for Experimental Hematology in New York, 1996. *Experimental Hematology* 24:1140. Abstract 69.
12. Hagemester FB, McLaughlin P, Rodriguez MA, Cox JD, Ha CS, Romanguera J, Sarris A, Younes A, **Bachier C**, Preti A, Cabanillas F. The Pretreatment Serum Beta-2 Microglobulin ( $\beta_2M$ ) is the most Important Feature Predicting Freedom From Progression (FFP) in Clinically Staged (CS) I-II Hodgkin's Disease (HD) Treated with NOVP and Extended Field Radiotherapy. 37th Annual Meeting of the American Society of Hematology. *Blood*. 86(10):2108, 1995.
13. Preti HA, Plunkett W, Sarris HA, Younes A, Hagemester F, Rodriguez MA, Romaguera J, McLaughlin P, **Bachier C**, Cabanillas F. Preliminary Results of a Phase II Trial of Topotecan in Patients with Relapsed Lymphoma. 37th Annual Meeting of the American Society of Hematology. *Blood*. 86(10):3268, 1995.
14. **Bachier C**, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Haley T, Cabanillas F, Champlin R, Berenson R, Heimfeld S, Deisseroth AB. Autologous Bone Marrow Transplantation (ABMT) in Patients with Follicular Non-Hodgkin's Lymphomas (FNHL) Using CD34+ Selection and Retroviral Hematopoietic Transduction. *Journal of Investigative Medicine* 44(3):279A, 1996.
15. T, Kavanagh J, Calvert L, Rahman Z, Holmes F, Hortobagyi G, Heimfeld S, Berenson R, Holzmayer T, Mechetner E, Champlin R, Deisseroth AB. Multiple Drug Resistance (MDR-1) Genetic Chemoprotection Autologous Transplants of Retroviral Vector Mediated MDR-1 Stromal Transduced CD34 Selected Cells Generate Post-Transplant Bone Marrow Positive for Viral MDR-1 Sequences. Proceedings of the 32nd Annual Meeting of the American Society for Clinical Oncology. May 1996. Abstract 583.
16. **Bachier C**, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Haley T, Cabanillas F, Champlin R, Berenson R, Heimfeld S, Deisseroth AB. CD34+ Selection and Retroviral Hematopoietic Gene Marking to Determine the Role of Bone Marrow and Peripheral Blood Grafts on Relapse in Patients with Follicular Non-Hodgkin's Lymphoma (FNHL). Proceedings of the 32nd Annual Meeting of the American Society for Clinical Oncology. May 1996. Abstract 574.

17. **Bachier C**, Giles RE, Ellerson E, Hanania EG, Garcia-Sanchez F, Haley T, Cabanillas F, Champlin R, Berenson R, Heimfeld S, Deisseroth AB. Retroviral Gene Marking in Relapsed Follicular Non-Hodgkin's Lymphoma (FNHL) to Determine the Origin of Relapse Following Autologous Bone Marrow (ABMT) and Peripheral Blood Stem Cell Transplant (PSCT). Proceedings of the 87th Annual Meeting of the American Association for Cancer Research. April 1996. Abstract 1398.
18. Hanania EG, Giles RE, Claxton D, Zu Z, **Bachier C**, Hamer J, Ellerson D, Wang T, Su Y, Haley T, Kavanagh J, Calvert L, Rahman Z, Holmes F, Heimfeld S, Berenson R, Holzmayer T, Mechetner E, Champlin R, Deisseroth AB. Post-Transplant Frequency of Genetically Modified Cells Using Retroviral-Mediated Multiple Drug Resistance (MDR-1) Stromal Transduction Protocol in Breast and Ovarian Cancers. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research. April 1996. Abstract 2363.
19. **Bachier C**, Castro J, Grayson G, Oliverson S, Meneghetti C, Moore A, Childs C, Nanez A, Huerta J, Botello J, LeMaistre CF. Effect of Age on the Ability to Collect Autologous Peripheral Stem Cells (PSC) after Granulocyte Colony Stimulating Factor (G-CSF) Priming. 2nd Annual Scientific Meeting of the American Society for Blood and Marrow Transplantation in San Diego, 1996. Abstract 51.
20. van Besien K, Ha CS, Forman A, McLaughlin P, Rodriguez A, Romaquera J, Hagemester F, Younes A, **Bachier C**, Sarris A, Cox J, Cabanillis F. Central Nervous System (CNS) Recurrence of Lymphoma (NHL) in the Adult: Incidence, Prognosis, and Impact of Treatment. Proceedings of the 38th Annual Meeting of the American Society of Hematology. *Blood*. 88(10):356, 1996.
21. J Castro, HL Bentch, L Smith, S Kalter, **C Bachier**, C Meneghetti, A Moore, S Oliverson, LeMaistre CF. Prolonged Clinical Remission in Patients (pts.) with Inflammatory Bowel Disease (IBD) after High Dose Chemotherapy (HDC) and Autologous Blood Stem Cell Transplantation (ABSCT). Proceedings of the 38th Annual Meeting of the American Society of Hematology. *Blood*. 88(10):519, 1996.
22. Cabanillas F, Champlin R, Berenson R, Heimfeld S, Deisseroth AB. Retroviral Gene Marking to Identify the Origin of Relapse Following Autologous CD34 Positive Bone Marrow (BM) and Peripheral Blood (PB) Transplantation in Follicular Non-Hodgkin's Lymphoma (FNHL). Proceedings of the 38th Annual Meeting of the American Society of Hematology. *Blood*. 88(10):1707, 1996.
23. Romaguera J, Khouri I, Kantarjian H, Terol-Castera MJ, Rodriguez MA, Hagemester FB, McLaughlin P, Younes A, Sarris A, **Bachier C**, Preti HA, Pugh W, Garcia-Conde J, Champlin R, Cabanillas F. HCVAD/MTX-ARAC: A New Effective Regimen for Diffuse and Nodular Mantle Cell Lymphoma (MCL). Proceedings of the 38th Annual Meeting of the American Society of Hematology. *Blood*. 88(10):2261, 1996.
24. Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemester F, **Bachier C**, Preti A, Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. *Ann Oncol*. 8 Suppl 1:129-31, 1997.

25. Lanzkron S, **Bachier C**, Alexander L, Meneghetti C, Nanez A, Botekko J, Huerta J, Childs C, LeMaistre CF. Incidence of graft vs. host disease in patients undergoing allogeneic peripheral blood stem cell transplants or bone marrow transplants on cyclosporine and steroid prophylaxis. *Blood*. 90(10):4499, 1997.
26. Romaguera J, Hagemester P, McLaughlin P, Rodriguez MA, **Bachier C**, Preti S, Sarris AH, Weber D, Younes A, Cabanillas F. Phase II study of Taxol in combination with Mitoxantrone and Ifosfamide (MINT) with consolidation ESHAP for lymphomas. Proceeding of the 39<sup>th</sup> Annual American Society of Hematology. *Blood*. 90(10):835, 1997.
27. **Bachier C**, Lanzkron S, Hougham M, Meneghetti C, Nanez A, Botello J, Huerta J, Slanham S, Childs C, Muller TE, Armstrong RD, Weber S, LeMaistre CF. Ex-vivo expansion of stem cells (SC) for hematopoietic reconstitution following high dose chemotherapy (HDC) for breast cancer. Proceeding of the 39<sup>th</sup> Annual American Society of Hematology. *Blood*. 90(10):1632, 1997.
28. Gokmen E, Raaphorst FM, **Bachier C**, LeMaistre CF, Muller TE, Armstrong RD, Boldt DH, Teale JM. B- and T- cells obtained from ex vivo-expanded bone marrow (BM) mononuclear cell (MNC) transplant recipient exhibit Ig H and TCRVB CDR3 repertoires similar to that seen after conventional hematopoietic stem cell transplantation. Proceeding of the 39<sup>th</sup> Annual American Society of Hematology. *Blood*. 90(10):2403, 1997.
29. Lanzkron S, **Bachier C**, Ward JA, Alexander L, Trencklebach B, Childs C, LeMaistre CF. Number (Num) of Leukopheresis (LP) Collection is a Separate Predictor of Engraftment (EGF) After Peripheral Blood Stem Cell (PBSE) Transplant. Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):497, 1998.
30. Pecora AL, Preti R, Jennis A, Goldberg S, Stiff P, **Bachier C**, LeMaistre CF, Douville J, Armstrong RD, Smith A. Aastrom Replicell <sup>TM</sup> System Expanded Bone Marrow Enhances Hematopoietic Recovery in Patients Receiving Low Doses of G-CSF Primed Blood Stem Cells. Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):507, 1998.
31. Repertoire Diversity of T-Cell Subsets and B-Cells is Durable after Transplantation of Ex Vivo Expanded Hematopoietic Cells as the Only Source of Graft. Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):1836, 1998.
32. Vij R, Atkins D, Brown R, Goodnough LT, Khoury H, Wetervelt P, Biondo M, Freytes C, **Bachier C**, DiPersio J. Lack of Efficacy of high-Dose Chemotherapy (HDCT) and Autologous Stem Cell Transplantation (ASCT) For High Risk Locoregional Recurrence of Breast Cancer. Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):1909, 1998.
33. Sarris AH, Psyrris A, Romaguera J, Hagemester F, McLaughlin P, **Bachier C**, Mesina O, Adams LM, Cabanillas F. Phase I/II Trial of Infusional Vinorelbine in Relapsed or Refractory Lymphoma. Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):2562, 1998.

34. **Bachier C**, Gokmen E, Teale J, Lanzkron S, Hougham M, Nanez A, Huerta J, Childs C, LeMaistre CF. Randomized Trial of Granulocyte Colony Stimulating Factor (G-CSF) Versus Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) for mobilization of Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplantation in Patients with Hematological Disorders. Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):2813, 1998.
35. **Bachier C**, Lanzkron S, Childs C, Nanez A, Huerta J, LeMaistre CF. Overnight (O/N) Storage of Peripheral Blood Stem Cells (PBSC) Affects Viability But Does Not Affect the Number of Progenitor or CD34+ Cells. Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):4278, 1998.
36. **Bachier C.**, Teale J, Lanzkron S, Hougham M, Nanez A, Huerta J, Childs C, LeMaistre CF. Concurrent and Sequential Administration of Interleukin-2 (IL-2) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) for Immune Activation Following High Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT). Proceeding of the 40<sup>th</sup> Annual American Society of Hematology. *Blood*. 92(10):4550, 1998.
37. **Bachier C**, Lanzkron S, Grayson G, Hougham M, Childs C, LeMaistre CF. Randomized Trial of Granulocyte Colony Stimulating Factor (G-CSF) Versus Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Versus Concurrent G0CSF/GM-CSF for Mobilization of Allogeneic Peripheral Blood Stem Cells (PBSC). Proceeding of the 41<sup>st</sup> Annual American Society of Hematology, 1999.
38. **Bachier C**, Teale J, Lanzkron S, Hougham M, Nanez A, Huerta J, Childs C, LeMaistre CF. Concurrent and Sequential Administration of Interleukin-2 (IL-2) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) for Immune Activation Following High Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT). American Society for Blood and Marrow Transplant, 2000.
39. Interleukin-2 (IL-2) and Granulocyte-Macrophage colony Stimulating Factor (GM-CSF) for Immune Activation Following Autologous Stem Cell Transplant (ASCT) Increase Lymphocyte subsets more than either drug alone. American Society of Clinical Oncology. 2000.
40. **Bachier C**, McMasters R, Cano G, LeMaistre CF, Moyer MP. M3:20<sup>TM</sup> Media Improves the Activation, Maturation and Long Term Growth of Dendritic Cells (DC) Derived From the Peripheral Blood. Proceedings of the 42<sup>nd</sup> Annual American Society of Hematology. *Blood*. 2000.
41. LeMaistre CF, **Bachier CR**, Cloud RS, Cayce K, Alexander L, Wall DA, Gonzales B, Shaughnessy PJ. Reduced Intensity Preparative Regimens (RIR) Offer No Cost Savings Over Myeloablative Regimens (MR) in Matched Related Allogeneic Stem Cell Transplant. Proceedings of the 43<sup>RD</sup> Annual American Society of Hematology, 2001. *Blood*. 98(11): 2001 Abstract 798.

42. Shaughnessy P, Tran H, Andersson B, Sprigg-Saenz H, Ornstein D, Ririe D, **Bachier C**, LeMaistre CF. Pharmacokinetics (PK) and Toxicity of Once Daily Dosing of Intravenous Busulfan (IVBU) in a Reduced Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation (ASCT). Proceedings of the 43<sup>RD</sup> Annual American Society of Hematology, 2001. *Blood*. 98(11): 2001. Abstract 5041.
43. Shaughnessy P, Tran H, Andersson B, Sprigg-Saenz H, Splichal J, Alexander W, Ornstein D, Ririe D, **Bachier C**, LeMaistre CF. Pharmacokinetics (PK) of Once Daily Dosing of Intravenous Busulfan (IVBU) in a Reduced Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation (ASCT). Submitted to ASBMT meeting 2002. *Biology of Blood and Marrow Transplantation*. 8(2): 2002. Abstract 76.
44. LeMaistre CF, **Bachier CR**, Cloud RS, Cayce K, Alexander L, Wall DA, Gonzales B, Shaughnessy PJ. Both Charges and Reimbursement for Reduced Intensity Preparative Regimens (RIR) Are Comparable to Myeloablative Regimens (MR) in Matched Related Allogeneic Stem Cell Transplant (ASCT). *Biology of Blood and Marrow Transplantation*. 8(2): 2002. Abstract 64.
45. Shaughnessy PJ, **Bachier C**, Long L, LeMaistre CF, Gaziitt Y. Comparison between G-CSF and GM-CSF for mobilization of dendritic cells, CD34+ cells, and CD3+ cells in normal donors. *Blood*. 100(11):827a, 2002.
46. Trevino A, Shaughnessy PJ, Hudak P, Lanzkron S, **Bachier C**, LeMaistre CF. Digene Hybrid Capture (DHC) CMV DNA Assay Compared to CMV Culture and Incidence of CMV Disease in Allogeneic Hematopoietic Stem Cell Transplantation (ASCT). *Biology of Blood and Marrow Transplantation*. 9(2): 2003 Abstract 137.
47. Shaughnessy PJ, **Bachier C**, Grimley M, LeMaistre CF. Phase II Study of Denileukin Difitox (ONTAK<sup>®</sup>) in the Treatment of Steroid Resistant Acute Graft Versus Host Disease (AGVHD). *Biology of Blood and Marrow Transplantation*. 9(20): 2003 Abstract 98.
48. Study of Denileukin Difitox (ONTAK<sup>®</sup>) in the Treatment of Steroid Resistant Acute Graft Versus Host Disease (AGVHD). *Blood*. 102(11): 2003 Abstract 715a.
49. **Bachier C**, Shaughnessy P, Wall D, Grimley M, Carrum G, Freytes C, Callander N, Walsh T, LeMaistre C. Valganciclovir for the Early Prophylaxis of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplantation. *Blood*. 104(11).2004. Abstract 5074.
50. Walsh T, **Bachier C**, Shaughnessy P, Freytes C, Callander N, LeMaistre CF, Grimley, Bradshaw P. Efficacy of Fluconazole Prophylaxis for Autologous Peripheral Blood Stem Cell Transplantation: Results of a Prospective, Randomized, Controlled, Multi-center, Open Label Study. *Blood*. 104(11).2004. Abstract 5096.
51. Shaughnessy P, **Bachier C**, Nanez A, Akay C, LeMaistre CF, Gazitt Y. Comparison between G-CSF and GM-CSF for Mobilization of Dendritic Cells, CD34+ Cells, and CD3+ Cells in Normal Donors. *Blood*. 104(11). 2004. Abstract 2870.

52. Shaughnessy PJ, **Bachier C**, Alexander L, Bowen B, LeMaistre CF. Intravenous busulfan dosed four times daily or once daily as part of the standard BuCy preparative regimen for allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*. 11(2):37. 2005
53. **Bachier C**, Shaughnessy P, Wall D, Grimley M, Carrum G, Freytes C, Callander N, Walsh T, LeMaistre CF. Valganciclovir for the prophylaxis of early cytomegalovirus (CMV) infection after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*.11(2):90-91. 2005.
54. Walsh TL, **Bachier C**, Shaughnessy P, Freytes CO, Callander N, LeMaistre CF, Grimley M, Bradshaw P. Efficacy of fluconazole prophylaxis for autologous peripheral blood stem cell transplantation: Results of a prospective, randomized, controlled, multicenter, open label study. *Biology of Blood and Marrow Transplantation*. (11)2:106. 2005.
55. Shaughnessy PJ, **Bachier C**, Grimley M, Freytes CO, Callander NS, Essell JH, Flomenberg N, Selby G, LeMaistre CF. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*. 11(3):188-193. 2005.
56. **Bachier, C.R.**, Shaughnessy, P., Wall, D., Grimley, M., LeMaistre, C.F. Interleukin-2 (IL-2) and Granulocyte-Macrophage Stimulation Factor (GM-CSF) for Treatment of Relapse after Allogeneic Stem Cell Transplant (ASCT). 2006 BMT Tandem Meeting in Honolulu, HI. *Biology of Blood and Marrow Transplantation*. 12(2):56, Feb. 2006. Abstract 157.
57. Aberle, M.F., **Bachier, C.**, LeMaistre, F.C, Shaughnessy, P.J. Valganciclovir is Effective in the Preemptive Treatment of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplant (ASCT). 2006 BMT Tandem Meeting in Honolulu, HI. *Biology of Blood and Marrow Transplantation*. 12(2): 136, Feb. 2006. Abstract 392.
58. Hoerster, C.M., **Bachier, C.**, LeMaistre, C.F., Shaughnessy, P. Descriptive Analysis on the Role and Outcomes of Psychological Evaluation and Intervention in Patients Undergoing Stem Cell Transplant. 2006 BMT Tandem Meeting in Honolulu, HI. *Biology of Blood and Marrow Transplantation*. 12(2): 142, Feb. 2006 Abstract 408.
59. **Bachier, C.R.**, Shaughnessy, P, Smith, B., Salinas, R., LeMaistre, C.F. Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor is an Alternative to Donor Lymphocyte Infusion for Relapse after Allogeneic Stem Cell Transplantation and is Associated with Increase Immune Effector Cells and Polarization to Type 2 Dendritic Cells. 2007 ASH Annual Meeting Abstracts in Atlanta, GA. *Blood*. 11(1) 110: 2007. Abstract 1647.
60. LeMaistre, J., **Bachier, C.**, Smith, B., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan Cyclophosphamide is well tolerated and effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation. 2007 ASH Annual Meeting Abstracts in Atlanta, GA. *Blood*. 11(1) 110: 2007 Abstract 1996.

61. Potter, G.W., **Bachier, C.**, Smith, B., Hougham, M., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan and Fludarabine is Well-Tolerated and Effective in Older Heavily Treated Patients Prior to Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplant. 2007 ASH Annual Meeting Abstracts in Atlanta, GA. *Blood*. 11(2) 110: 2007 Abstract 4950.
62. LeMaistre, J., **Bachier, C.**, Smith, B., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan Cyclophosphamide is Well-Tolerated and Effective Prior to Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*. 14(2) Sup2: 111, 2008.
63. Potter, G.W., **Bachier, C.**, Smith B., Houghman, M., LeMaistre, C.F., Shaughnessy, P.J. Once Daily Busulfan and Fludarabine is Well-Tolerated and Effective in Older Heavily Treated Patients Prior to Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplant. *Biology of Blood and Marrow Transplantation*. 14(2) Sup2: 120, 2008.
64. **Bachier, C.R.**, Shaughnessy, P., Smith, B., Salinas, R., LeMaistre, C.F. Immune Activation with Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor for Treatment of Relapse after Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*. 14(2) Sup2: 131-132, 2008.
65. Lopez-Gonzalez, G., LeMaistre, C.F., **Bachier, C.**, Smith, B., Chan, K.W., Grimley, M., Cain, W., Delgado, E., Kaleel, S., Shaughnessy, P. Clinical and Cost Outcomes of Double Umbilical Cord Blood Versus Bone Marrow and Peripheral Blood Unrelated Hematopoietic Stem Cell Transplants. *Blood*. 112(11): 355-356, 2008.
66. Delgado, E., LeMaistre, C.F., **Bachier, C.**, Smith, B., Lopez-Gonzalez, G., Houghman, M., Kaleel, S., Shaughnessy, P. Cost Analysis of Mobilization and Autologous Transplantation in Patients Who Received AMD 3100 after Failing Standard Mobilization. *Blood*. 112(11): 749-750, 2008.
67. Lopez-Gonzalez G, LeMaistre CF, **Bachier C**, Smith B, Chan KW, Grimley M, Cain W, Delgado E, Kaleel S, Shaughnessy P. Clinical and cost outcomes of double umbilical cord blood versus bone marrow and peripheral blood unrelated donor hematopoietic stem cell transplants. *Biology of Blood and Marrow Transplantation*. 14(2) Suppl 2: 277, 2009.
68. Delgado E, LeMaistre CF, **Bachier C**, Smith B, Lopez-Gonzalez G, Hougham M, Kaleel S, Shaughnessy P. Cost analysis of mobilization and autologous transplantation in patients who received AMD3100 after failing standard mobilization. *Biology of Blood and Marrow Transplantation*. 15(2) Suppl 2: 248, 2009.
69. Potter G.W., LeMaistre, C.F., Shaughnessy, P., Islas, M., Huerta, J. **Bachier, C.** Collection of Autologous Peripheral Blood Stem Cells Using the COBE Spectra is Associated with Higher CD34+ Yields and Requires Less Collection Time Than the Fresenius AS104 Cell Separator. *Blood*. 114(22): 848, 2009.

70. Martin PJ, **Bachier CR**, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. *Biol Blood Marrow Transplant*; 15(7):777-84, 2009.
71. M. Islas-Ohlmayer, G.W. Potter, P. Shaughnessy, C.F. LeMaistre, J. Huerta, J. Folkert, **C. Bachier** Hematopoietic Stem Cell Apheresis Products With High Mid-Collection WBC Counts Are An Accurate Indicator Of The Final Product WBC Count And Are Associated With Transplant Related Adverse Events. *Biology of Blood and Marrow Transplantation* February 2010 (Vol. 16, Issue 2, Supplement, Page S212)
72. Richard T Maziarz, **Carlos Bachier**, Steve Goldstein, Steven Devine, Jose Leis, Kenneth R Cooke, Robert Perry, Wouter Van't Hof, Robert J Deans, Hillard M Lazarus Stromal Stem Cell Therapy for Prophylaxis of Acute GVHD: Preliminary Results from a Phase 1 Trial February 2011

**C. Book Chapters:**

1. **Bachier C**, Deisseroth AD. Gene Therapy of Solid Tumors and Hematopoietic Neoplasms. *In Blood Stem Cell Transplantation.* JN Winter, ed. Kluwer Acad Pub. (Norwell, MA), pp 3-27, 1997.
2. **Bachier C**, LeMaistre CF. Immunotoxin Therapy of Graft - Versus – Host Disease. *Monoclonal Antibody-Based Therapy of Cancer.* ML Grossbard, ed. Mercel Dekker Pub., pp 211-228, 1998.